Tag: short-acting insulin market outlook

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Short-Acting Insulin Market Today And What Is Its Future Size?

There has been a consistent increase in the market size of short-acting insulin in past years. It is expected to escalate from its $11 billion value in 2024 to approximately $11.54 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 4.8%. Factors contributing to this incline during the historical period include a rise in type 1 diabetes sufferers, an aging population, an uptick in funding for research and development, a surge in reported diagnosis, and accelerated urbanization.

In the coming years, the market size of short-acting insulin is predicted to experience robust growth, potentially escalating to “$14.14 billion in 2029, with a compound annual growth rate (CAGR) of 5.2%. The projected growth within this period can be associated with increased governmental initiatives and support, swift advancements in production techniques, a greater adoption of insulin therapy, and the emergence of personalized medicine. The forecast period is expected to witness major trends such as improvement in insulin delivery devices and technologies, the introduction of innovative fast-acting insulin analogs, the creation of biosimilars, a move towards patient-focused care, and advancements in drug formulation.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

What Are The Primary Factors Supporting The Short-Acting Insulin Market Expansion?

The heightened occurrence of type 1 diabetes is likely to drive the expansion of the short-acting insulin market. This autoimmune condition, in which insulin-producing cells are destroyed by the body, necessitates lifelong insulin treatment. Factors such as genetics, environmental triggers, and a rise in autoimmune disorders are behind the growing prevalence of Type 1 diabetes. Short-acting insulin assists in the management of type 1 diabetes by enabling prompt blood sugar regulation and emulating the natural insulin reaction. Diabetes Australia, a body dedicated to raising diabetes awareness, stated that in 2022, around 134,000 Australians were living with Type 1 diabetes. This number increased to 135,423 in 2023. Consequently, the growing occurrence of type 1 diabetes is propelling the expansion of the short-acting insulin market.

Which Sub-Segments Are Driving Growth Within The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Future-Focused Trends Are Anticipated In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are focusing on innovative products such as insulin pods to provide continuous insulin infusion and adherence for individuals with diabetes. An insulin pod refers to a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. For instance, in April 2023, Insulet Corporation, a US-based medical device company, announced U.S. Food and Drug Administration (FDA) clearance for Omnipod GO, a groundbreaking basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device offers continuous insulin delivery without the need for a separate controller. Omnipod GO simplifies diabetes management by eliminating daily injections and providing pre-programmed insulin rates. With its user-friendly design and pharmacy accessibility, it enhances convenience for both patients and healthcare providers. This launch reinforces Insulet’s commitment to improving diabetes care through innovative technology.

Which Companies Hold A Competitive Edge In The 551 Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Dominates The Short-Acting Insulin Market Today?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Short-Acting Insulin Market Growth Performance Trended Historically, And What Lies Ahead?#_x000D_

In recent times, the market for short-acting insulin has seen consistent growth. Anticipated to escalate from $11 billion in 2024 to $11.54 billion in 2025, it is predicted to exhibit a compound annual growth rate (CAGR) of 4.8%. The historical growth can be credited to factors such as the surge in the population with type 1 diabetes, the escalating elderly population, an influx in funds for research and development, increasing number of diagnosed cases, and rising urbanization._x000D_

_x000D_

The market of short-acting insulin is predicted to experience significant expansion in the upcoming years, increasing to $14.14 billion by 2029 with a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period can be linked to various factors including enhancement in government initiatives, increased state support, promptly evolving innovations in production, a surge in the utilization of insulin therapy, and the emergence of personalized healthcare. The forecast period is expected to witness major trends like advancements in insulin delivery gadgets and technology, pioneering fast-acting insulin analogs, progress in the production of biosimilars, transitioning towards patient-focused care, along with progression in formulation._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Short-Acting Insulin Market?#_x000D_

The surge in the incidence of type 1 diabetes is anticipated to propel the expansion of the short-acting insulin market. Type 1 diabetes is an autoimmune disorder in which the body eliminates cells responsible for producing insulin, necessitating permanent insulin treatment. The escalating occurrence of Type 1 diabetes is attributed to genetic influences, environmental catalysts, and a rise in autoimmune diseases. Short-acting insulin is beneficial in managing type 1 diabetes by offering swift blood sugar regulation and simulating the natural insulin reaction. For instance, data by Diabetes Australia, a group dedicated to increasing diabetes awareness, revealed that approximately 134,000 Australians had Type 1 diabetes in 2022. This count escalated to 135,423 in 2023. Hence, the rise in the incidence of type 1 diabetes is facilitating the growth of the short-acting insulin market._x000D_

_x000D_

#How Is the Short-Acting Insulin Market Segmented?#_x000D_

The short-acting insulin market covered in this report is segmented – _x000D_

_x000D_

1) By Formulation: Regular Insulin, Rapid-Acting Insulin_x000D_

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges_x000D_

3) By Route Of Administration: Subcutaneous, Intravenous_x000D_

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes_x000D_

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin _x000D_

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Short-Acting Insulin Market Growth?#_x000D_

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Short-Acting Insulin Market?#_x000D_

The primary players in the short-acting insulin market are directing their efforts towards the development of innovative items such as insulin pods, which ensure seamless insulin infusion and adherence for individuals with diabetes. An insulin pod is a tubeless, wearable system that offers a continuous supply of insulin for those managing diabetes. For example, in April 2023, Insulet Corporation, a medical device company based in the US, received clearance from the U.S. Food and Drug Administration (FDA) for their Omnipod GO: a trailblazing basal-only insulin pod aimed at adults with type 2 diabetes. This tubeless, wearable equipment dispenses insulin continuously, eliminating the need for a separate controller. The Omnipod GO simplifies diabetes control by removing the necessity for daily injections, also offering pre-programmed insulin rates. With its user-friendly interface and the ease of getting it from a pharmacy, it bolsters convenience for patients and healthcare providers alike. This product launch further underscores Insulet’s dedication to enhancing diabetes care with cutting-edge technology._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report_x000D_

_x000D_

#How Is the Short-Acting Insulin Market Defined and What Are Its Core Parameters?#_x000D_

Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Short-Acting Insulin Market from 2024 to 2025?

The market for short-acting insulin has experienced significant growth in recent times. Its value is projected to increase from $11.00 billion in 2024 to $11.65 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.9%. This growth during the historic period is a result of several factors including a rise in the number of people with type 1 diabetes, an increasing older population, a boost in research and development funding, the occurrence of diagnosed cases, and an uptick in urbanization.

What Is the Projected Market Size of the Short-Acting Insulin Market?

The market size of short-acting insulin is set to witness substantial expansion in the upcoming years, with projections pointing to a growth to $14.47 billion in 2029, boasting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this anticipated surge within the forecast period encompass escalated activities by governing bodies, amplified government backing, fast-paced product innovations, a spike in embracing insulin therapy, and an upswing in personalized medicine. Foreseen trends within this period encompass progress in the realm of insulin delivery devices and technologies, cutting-edge rapid-acting insulin analogs, growth in biosimilars, a paradigm shift towards patient-focused care, and breakthroughs in formulation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Who are the Major Competitors in the Short-Acting Insulin Market Outlook?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

What Is Fueling Growth in the Short-Acting Insulin Market?

The boost in the short-acting insulin market can be attributed to the escalating occurrence of type 1 diabetes. This autoimmune illness is characterized by the body’s destruction of insulin-producing cells, leading to a lifetime requirement for insulin therapy. Genetic predispositions, environmental catalysts, and an overall increase in auto-immune disorders are fuelling the ascending prevalence of type 1 diabetes. Short-acting insulin proves beneficial in managing type 1 diabetes, offering quick blood sugar regulation and emulating the natural insulin action in the body. For example, Diabetes Australia, an agency focusing on heightening diabetes awareness, reported that in 2022, around 134,000 Australians had type 1 diabetes and this number rose to 135,423 in 2023. Therefore, the expansion of the short-acting insulin market can be directly linked to the upsurge in type 1 diabetes cases.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Which Short-Acting Insulin Market Segments Are Growing the Fastest?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Which Industry Trends Are Shaping the Future of the Short-Acting Insulin Market?

Key players in the short-acting insulin sector have shifted their attention toward the development of novel products such as insulin pods. These tools, wearable and tubeless, continue the infusion of insulin for individuals struggling with diabetes. Take for instance the Insulet Corporation, an American medical device corporation, who in April 2023 received clearance from the U.S. Food and Drug Administration (FDA) for their latest product, Omnipod GO. This innovative, basal insulin-only pod is particularly targeted toward adults dealing with type 2 diabetes. Besides not requiring a separate controlling device, this wearable contraption simplifies the management of diabetes by eradicating the necessity of daily injections and offering pre-set insulin rates. The design of Omnipod GO is user-centric, easy to access in pharmacies, thus promoting convenience for the patients as well as healthcare service providers. Such a launch accentuates Insulet’s dedication to enhancing diabetes treatment through cutting-edge technology.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Countries Are Leading the Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287

This Report Delivers Insight On:

1. How big is the short-acting insulin market, and how is it changing globally?

2. Who are the major companies in the short-acting insulin market, and how are they performing?

3. What are the key opportunities and risks in the short-acting insulin market right now?

4. Which products or customer segments are growing the most in the short-acting insulin market?

5. What factors are helping or slowing down the growth of the short-acting insulin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#How Has the Short-Acting Insulin Market Growth Performance Trended Historically, And What Lies Ahead?#_x000D_

In recent times, there has been notable growth in the market size of short-acting insulin. The market, which stood at $11.00 billion in 2024, is projected to scale up to $11.65 billion by 2025, expanding at a compound annual growth rate (CAGR) of 5.9%. The upward trend in the past periods is due to factors such as the growing population of type 1 diabetics, an aging population, increased funding for research and development, a rise in diagnosis rates, and escalating urbanization._x000D_

_x000D_

The market for short-acting insulin is projected to experience a robust expansion in the forthcoming years. The market size is anticipated to swell to $14.47 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. The predicted upswing during the forecast timeframe is ascribed to the amplified initiatives from the government, augmented government backing, swift production innovations, growing adoption of insulin therapy, and the emergence of personalized medicine. Key trends expected in the forecast span include progress in insulin delivery devices and technologies, the creation of innovative rapid-acting insulin analogs, the advent of biosimilars, a transition towards patient-centric healthcare, and advancements in formulation._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Short-Acting Insulin Market?#_x000D_

The growth of the short-acting insulin market is being propelled by the rising occurrence of type 1 diabetes. This autoimmune disease results in the destruction of insulin-producing cells in the body, necessitating consistent insulin treatment. Factors such as genetics, environmental influences, and an uptick in autoimmune disorders contribute to the escalating prevalence of Type 1 diabetes. Short-acting insulin is essential in controlling type 1 diabetes, as it swiftly regulates blood sugar levels and imitates the natural insulin reaction. To highlight this, data from Diabetes Australia, in their 2023 report, pointed out the increased number of Australians diagnosed with Type 1 diabetes; from approximately 134,000 in 2022 to 135,423 in 2023. As a result, the short-acting insulin market is experiencing robust growth due to the rising incidence of type 1 diabetes._x000D_

_x000D_

#Which Key Market Segments Comprise the Short-Acting Insulin Market and Drive Its Revenue Growth?#_x000D_

The short-acting insulin market covered in this report is segmented –_x000D_

_x000D_

1) By Formulation: Regular Insulin, Rapid-Acting Insulin_x000D_

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges_x000D_

3) By Route Of Administration: Subcutaneous, Intravenous_x000D_

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes_x000D_

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin_x000D_

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Short-Acting Insulin Market Expansion Across the Globe?#_x000D_

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Key Market Trends in theShort-Acting Insulin Market Over the Coming Years?#_x000D_

In the short-acting insulin market, leading corporations are channeling their efforts into creating innovative new products such as insulin pods. These pods, which are tubeless and can be worn on the body, offer an ongoing infusion of insulin, making it easier for those with diabetes to manage their condition. A typical example is Insulet Corporation, a medical device manufacturer from the US, that announced FDA approval for its product, the Omnipod GO, in April 2023. This avant-garde insulin pod, designed exclusively for Type 2 diabetic adults, delivers insulin constantly without necessitating a separate controller. The Omnipod GO rids patients of the daily injection routine and has pre-set insulin rates. Its easy-to-use design and availability in pharmacies increases its appeal not only to patients but also to medical professionals. This introduction further strengthens Insulet’s resolve to enhance diabetes treatment with trailblazing technology._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report_x000D_

_x000D_

#How Is the Short-Acting Insulin Market Conceptually Defined?#_x000D_

Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Short-Acting Insulin Market?

The increasing prevalence of type 1 diabetes is expected to fuel the growth of the short-acting insulin market in the future. Type 1 diabetes is an autoimmune condition where the body destroys insulin-producing cells, requiring lifelong insulin therapy. The rising prevalence of type 1 diabetes is driven by genetic factors, environmental triggers, and increasing autoimmune disorders. Short-acting insulin helps manage type 1 diabetes by providing rapid blood sugar control and mimicking natural insulin response. For example, in 2023, according to Diabetes Australia, an organization focused on raising awareness about diabetes, approximately 134,000 Australians were living with type 1 diabetes in 2022, and this number increased to 135,423 in 2023. Therefore, the growing prevalence of type 1 diabetes is driving the growth of the short-acting insulin market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

#How Does the ProjectedShort-Acting Insulin Market Growth Compare Over the Forecast Period?

The short-acting insulin market has experienced strong growth, increasing from $11.00 billion in 2024 to $11.65 billion in 2025 at a CAGR of 5.9%. Key drivers include a rising type 1 diabetes population, an aging demographic, increased research and development funding, a growing number of diagnosed cases, and rapid urbanization.

The short-acting insulin market is set to expand significantly, reaching $14.47 billion by 2029 at a CAGR of 5.6%. Growth factors include increased government initiatives, enhanced support for diabetes care, rapid advancements in insulin production, a higher adoption rate of insulin therapy, and the rise of personalized medicine. Key trends shaping the market include innovations in insulin delivery devices, the development of fast-acting insulin analogs, expansion of biosimilar options, a stronger focus on patient-centric diabetes care, and continuous improvements in insulin formulations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287

What Are the Key Market Innovations in theShort-Acting Insulin Market Over the Coming Years?

Companies in the short-acting insulin market are developing innovative products like insulin pods to provide continuous insulin infusion for diabetes management. An insulin pod is a tubeless, wearable device that delivers insulin continuously, offering greater convenience and improved adherence. For example, in April 2023, Insulet Corporation received FDA clearance for its Omnipod GO, a basal-only insulin pod designed for adults with type 2 diabetes. This device eliminates the need for daily injections, providing pre-programmed insulin rates and enhancing patient convenience.

Who Are the Top Companies Driving Innovation and Growth in theShort-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Key Market Segments Comprise the Short-Acting Insulin Market and Drive Its Revenue Growth?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Which Regions Are Emerging as Leaders in the Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2025, By The Business Research Company:

Venous Thromboembolism Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Deep Vein Thrombosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the market right now?

In recent times, there has been substantial growth in the size of the short-acting insulin market. The market which is predicted to be worth $11.00 billion in 2024, is estimated to reach $11.65 billion by 2025, signifying a compound annual growth rate (CAGR) of 5.9%. The past growth has largely been due to factors such as the rise in the population with type 1 diabetes, an aging population, a boost in funding for research and development, more cases being diagnosed, and increasing urbanization.

How fast Is the market expected to grow, and what’s its future value?

The market for short-acting insulin is forecasted to experience robust growth over the coming years, expanding to a valuation of $14.47 billion by 2029 with a 5.6% Compound Annual Growth Rate (CAGR). This projected development in the prediction period can be credited to increased government initiatives and support, swift production innovations, enhanced acceptance of insulin therapy, and the emergence of individualized medicine. Key trends for the prediction period comprise insulin delivery devices’ progressive enhancements and technologies, novel quick-acting insulin analogs, the production of biosimilars, a transition to more patient-focused care, and improvements in formulation.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which key drivers are propelling the market’s growth?

The short-acting insulin market is projected to expand due to the growing incidence of type 1 diabetes. This autoimmune disease results in the destruction of insulin-producing cells in the body, necessitating a lifetime of insulin treatment. Genetic factors, environmental triggers, and an increase in autoimmune disorders contribute to the surge in type 1 diabetes. Short-acting insulin aids in the management of type 1 diabetes by rapidly controlling blood sugar and simulating the body’s natural insulin response. For example, Diabetes Australia, an organization dedicated to raising diabetes awareness, reports that the number of Australians with type 1 diabetes was approximately 134,000 in 2022. By 2023, that number had grown to 135,423. As such, the rising incidence of type 1 diabetes is propelling the growth of the short-acting insulin market.

What are the key segments defining the market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Who are the key players steering the development of the market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

What are the key trends shaping the future of the market?

Leading businesses in the short-acting insulin market are prioritizing the development of inventive products like insulin pods for consistent insulin infusion and adherence among diabetes patients. Insulin pods are a wearable, tubeless insulin delivery device that facilitates ongoing insulin transfusion for managing diabetes. For example, in April 2023, Insulet Corporation, a medical device firm from the US, received clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary basal-only insulin pod named Omnipod GO, specifically designed for adults battling type 2 diabetes. This wearable, tubeless device facilitates consistent insulin delivery without the requirement of an additional controller. Omnipod GO makes diabetes management more straightforward by negating the need for daily injections and offering pre-defined insulin rates. Its user-friendly design and pharmacy availability makes it an accommodating solution for patients and healthcare providers alike. Insulet’s launch underlines the company’s dedication to enhancing diabetes care via groundbreaking technology.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287

Which regions are most influential in expanding the market?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Venous Thromboembolism Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Deep Vein Thrombosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Does the Projected Growth of the Short-Acting Insulin Market Compare Over the Forecast Period?

In the past few years, the short-acting insulin market has experienced robust growth. The size of the market is set to expand from $11.00 billion in 2024 to $11.65 billion in 2025, marking a compound annual growth rate (CAGR) of 5.9%. The soaring growth during the historic period can be traced back to factors such as a hike in the number of type 1 diabetes patients, a surging aged population, increased funds for research and development, the frequency of diagnosed cases, and a rise in urbanization.

In the next few years, the market size of short-acting insulin is projected to undergo significant growth, expanding to $14.47 billion in 2029 with a compound annual growth rate (CAGR) of 5.6%. This predicted growth during the forecast period can be attributed to factors such as heightened governmental initiatives, increased support from authorities, swift advancements in production procedures, rising prevalence of insulin therapy adoption, and the emergence of personalized medicine. The forecast period is also expected to witness certain trends in the form of advancements in insulin delivery mechanisms and technology, the creation of innovative fast-acting insulin analogs, the emergence of biosimilars, a shift towards prioritizing patient-focused care, and advancements in insulin formulation methods.

Which Primary Drivers Are Supporting the Continued Expansion of the Short-Acting Insulin Market?

The escalating incidences of type 1 diabetes are anticipated to stimulate the expansion of the short-acting insulin market in the future. Type 1 diabetes, an autoimmune disorder where the body eradicates cells that produce insulin, necessitates a lifetime requirement for insulin therapy. The augmented incidences of Type 1 diabetes are propelled by genetic elements, environmental instigators, and a rise in autoimmune conditions. By offering swift glucose control and imitating the natural insulin reaction, short-acting insulin plays a key role in managing type 1 diabetes. For example, Diabetes Australia, an organization based in Australia advocating diabetes awareness, stated that around 134,000 Australians were dealing with Type 1 diabetes in 2022. By 2023, this number had risen to 135,423. Consequently, the escalating incidences of type 1 diabetes are propelling the expansion of the short-acting insulin market.

Explore Comprehensive Insights Into The Global Short-Acting Insulin Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Who Are the Key Players Steering the Development of the Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

How Are Consumer Trends Shaping the Current and Future Landscape of the Short-Acting Insulin Market?

Key players in the short-acting insulin market are prioritizing the development of innovative items like insulin pods. These pods are tubeless, wearable insulin dispersion systems aiming to provide continuous insulin delivery for diabetes patients. For instance, the U.S. medical device firm, Insulet Corporation, announced in April 2023 that the U.S. Food and Drug Administration (FDA) had cleared the Omnipod GO. This is an innovative, basal-only insulin pod tailored to adult individuals suffering from type 2 diabetes. The device, which is tubeless and wearable, provides a constant insulin supply without requiring a separate controller. The Omnipod GO revolutionizes diabetes management by eradicating the need for daily injections and offering pre-set insulin rates. Its appealing design and pharmacy availability enhances convenience for patients and healthcare providers alike. This product launch confirms Insulet’s dedication to enhance diabetes treatment through creative technology.

Secure Your Global Short-Acting Insulin Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Primary Segments of the Short-Acting Insulin Market Are Driving Growth and Industry Transformations?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Which Geographical Regions Are Shaping the Short-Acting Insulin Market Growth?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Short-Acting Insulin Market Landscape?

Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food.

Browse Through More Similar Reports By The Business Research Company:

Venous Thromboembolism Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Deep Vein Thrombosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: